Healio Gastroenterology Current Issue

The following articles appeared in the print edition of Healio Gastroenterology.

Table of Contents

• Probiotics: Enthusiasm not supported by evidence Alex Young
• 7 Recent reports in interventional endoscopy Alex Young
• Oral drug shows efficacy up to 2 years in refractory UC Alex Young
• ‘Be clear-eyed’ when discussing expectations of probiotics with GI patients Edward V. Loftus Jr., MD
• Anti-TNF, thiopurine combination increase lymphoma risk in IBD Alex Young
• Anxiety, depression common among patients with cirrhosis Alex Young
• Balloon-assisted enteroscopy has good short-term efficacy for Crohn’s strictures Alex Young
• Barrett’s esophagus prevalence high after sleeve gastrectomy Monica Stonehill
• Comorbidities, not age, linked with worse safety outcomes for Entyvio, Stelara Alex Young
• Famotidine linked to improved outcomes in COVID-19 Monica Stonehill
• GEMINI: Entyvio safety profile favorable in long-term use Alex Young
• Increased coffee intake could avert deaths from liver disease Alex Young
• Number of antibiotic dispensations potentially linked with IBD development Alex Young
• Patients with IBD discontinue methotrexate at higher rate than thiopurines Alex Young
• PPIs associated with bone fractures in men with cirrhosis Alex Young
• Remicade plus thiopurine for Crohn’s yields better outcomes in first 6 months Monica Stonehill
• RHB-102 improves stool consistency in patients with IBS-D Monica Stonehill
• TAF therapy helps prevent mother to child transmission of HBV Alex Young
• Fatty acid synthase inhibitor reduces liver fat, markers of liver injury in NASH Monica Stonehill
• HBV drug well tolerated, reduces surface antigens in phase 2 trial Alex Young
• Liver stiffness worsens among NAFLD patients with stage 3 fibrosis Monica Stonehill
• Millennials, fatty liver predicted to feed cirrhosis diagnoses by 2040 Katrina Altersitz
• Multidisciplinary NAFLD approach improves liver-related, cardiovascular risk factors Monica Stonehill
• NASH resolves, fibrosis improves in 22% treated with growth factor analogue Katrina Altersitz
• Nidufexor significantly reduces ALT levels, hepatic fat in NASH Monica Stonehill
• NUC discontinuation shows durable immune control in e antigen-negative hepatitis B Alex Young
• Stivarga, Opdivo have similar survival outcomes in HCC Alex Young
• VIDEO: 'Glimmer of hope' in FMT for alcohol use disorder Alex Young
• VIDEO: No ‘hard-to-reach’ patients in HCV, just ‘hardly reached’ Alex Young
• VIDEO: ‘Promising’ treatment for alcoholic hepatitis in development Steven Flamm, MD
• ACG develops clinical guidelines for diagnosis, treatment of achalasia Monica Stonehill
• AGA recommends bidirectional endoscopy to evaluate iron deficiency anemia Monica Stonehill
• AMPK activator well tolerated, safe for NASH Monica Stonehill
• ‘Food is your medicine’: Advocating for nutrition policies Ana Maldonado-Contreras, PhD